PCN65 ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.262
https://www.valueinhealthjournal.com/article/S1098-3015(19)32640-3/fulltext
Section Title :
Section Order :
10210
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32640-3&doi=10.1016/j.jval.2019.09.262